Page last updated: 2024-12-05

penicillamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Penicillamine is a medication used to treat a variety of conditions, including rheumatoid arthritis, Wilson's disease, cystinuria, and heavy metal poisoning. It is a derivative of penicillin and was first synthesized in 1957. Penicillamine works by binding to heavy metals, such as copper and mercury, and removing them from the body. It also inhibits the production of certain enzymes that are involved in inflammation. Penicillamine is a highly effective treatment for rheumatoid arthritis, but it can cause a number of side effects, including skin rash, nausea, and liver damage. It is also important to note that penicillamine can interact with other medications, so it is important to talk to your doctor before taking it.'

Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5852
CHEMBL ID1430
CHEBI ID7959
SCHEMBL ID4343
MeSH IDM0016122
PubMed CID4727
CHEMBL ID13239
CHEBI ID50868
SCHEMBL ID57527
MeSH IDM0016122

Synonyms (267)

Synonym
KBIO1_000314
DIVK1C_000314
SPECTRUM_000283
d-mercaptovaline
metalcaptase
reduced d-penicillamine
d-penamine
reduced penicillamine
nsc-81549
(s)-penicillamine
d-penicillamine ,
d-3-mercaptovaline
d-valine, 3-mercapto-
distamine
SMP1_000042
SPECTRUM5_001196
penicilamina
3-sulfanyl-d-valine
penicillaminum
CHEBI:7959 ,
d-(-)-penicillamine
perdolat
cuprimine
cuprenil
artamine
metalcaptase (*hydrochloride*)
penicillamin
sufortan
distamine (*hydrochloride*)
trolovol
3-mercapto-d-valine
(2s)-2-amino-3-methyl-3-sulfanyl-butanoic acid
depen
mercaptyl
nsc81549
52-67-5
C07418
penicillamine
d-penicillamine, 98-101%
d-beta,beta-dimethylcysteine
NCGC00024359-04
(s)-3,3-dimethylcysteine
(-)-penicillamine
DB00859
(s)-2-amino-3-mercapto-3-methylbutanoic acid
depen (tn)
penicillamine (jan/usp/inn)
D00496
cuprimine (tn)
sufirtan
d,3-mercaptovaline
(s)-penicillamin
(d)-penicillamine
valine, 3-mercapto-, d-
(2s)-2-amino-3-methyl-3-sulfanylbutanoic acid
ccris 2904
penicillaminum [inn-latin]
hsdb 3378
alpha-amino-beta-methyl-beta-mercaptobutyric acid
beta,beta-dimethylcysteine
cupripen
penicilamina [inn-spanish]
nsc 81549
depamine
kuprenil
mercaptovaline
pendramine
einecs 200-148-8
beta-thiovaline
KBIO2_000763
KBIO3_001681
KBIO2_005899
KBIO2_003331
KBIOSS_000763
KBIOGR_000920
SPECTRUM2_001029
NINDS_000314
SPECTRUM4_000470
SPBIO_001217
SPECTRUM3_000541
BSPBIO_002181
IDI1_000314
NCGC00024359-05
NCGC00018283-01
P-1280 ,
CHEMBL1430 ,
bdbm50217941
(2s)-2-amino-3-methyl-3-sulfanylbutanoic acid3-sulfanyl-d-valine
P0147
d-beta-mercaptovaline
d 3 mercaptovaline
beta,beta dimethylcysteine
d penicillamine
EN300-52608
AKOS006237201
dtxcid4017069
dtxsid6037069 ,
cas-52-67-5
tox21_110899
unii-gnn1dv99gx
penicillamine [usan:usp:inn:ban:jan]
gnn1dv99gx ,
penicillamina
NCGC00024359-06
EPITOPE ID:113237
S1853
gtpl7264
penicillamine [mi]
penicillamine [ep impurity]
penicillamine [mart.]
penicillamine [who-dd]
penicillamine [usan]
penicillamine [usp-rs]
penicillamine [inn]
penicillamine [hsdb]
penicillamine [vandf]
penicillamine [jan]
penicillamine [orange book]
penicillamine [ep monograph]
penicillamine [usp monograph]
HY-B0300
VVNCNSJFMMFHPL-VKHMYHEASA-N
AM83710
SCHEMBL4343
(2s)-2-azanyl-3-methyl-3-sulfanyl-butanoic acid;hydrochloride
cid_92173
(2s)-2-amino-3-mercapto-3-methylbutanoic acid;hydrochloride
(2s)-2-amino-3-mercapto-3-methyl-butyric acid;hydrochloride
bdbm39346
STR02534
d-(-)-2-amino-3-mercapto-3-methylbutanoic acid
dimethyl cysteine
d-penicillamin
penicillamine, united states pharmacopeia (usp) reference standard
penicillamine, european pharmacopoeia (ep) reference standard
sr-01000000262
SR-01000000262-3
SR-01000000262-4
BCP17247
Q421239
penicillamine (cuprimine)
penicillamine,(s)
3-thio-d-valine
penicillamine-(racemic)
penicillamine-(d)
CCG-266197
P15236
M06142
Z234896485
penicillamine (usan:usp:inn:ban:jan)
penicillamine (usp monograph)
penicilamina (inn-spanish)
kelatin
penicillamine (ep monograph)
m01cc01
penicillamine (mart.)
atamir
penicillaminum (inn-latin)
penicillamine (usp-rs)
penicillamine (ep impurity)
nsc81988
NSC241261 ,
nsc-44656
nsc44656
2-amino-3-methyl-3-sulfanyl-butanoic acid
(2rs)-2-amino-3-methyl-3-sulfanyl-butanoic acid
dl-.beta.-mercaptovaline
dl-penicillamine
nsc-22880
dl-valine, 3-mercapto-
52-66-4
nsc22880
NCI60_001936
NCIOPEN2_000958
dl-beta,beta-dimethylcysteine
.beta.,.beta.-dimethylcysteine
dimethylcysteine
3,3-dimethylcysteine
CHEBI:50868 ,
2-amino-3-methyl-3-sulfanylbutanoic acid
3-mercaptovaline
(+-)-penicillamine
2-amino-3-mercapto-3-methylbutyric acid
dl-3-mercaptovaline
2-amino-3-mercapto-3-methylbutanoic acid
penicillamina [dcit]
d,l-penicillamine
dl-beta-mercaptovaline
brn 2039817
cysteine, 3,3-dimethyl-
valine, 3-mercapto-, l-
d-penicilamine
nsc 22880
einecs 200-147-2
valine, 3-mercapto-
valine, 3-mercapto-, dl-
nsc 44656
beta-mercaptovaline
SPECTRUM1500464
P-1290
STK249738
3-sulfanylvaline
HMS2094G19
CHEMBL13239
HMS500P16
P0025
HMS1920F10
AKOS000121093
HMS3259K09
BBL013214
2-amino-3-mercapto-3-methyl-butyric acid #3: please note: alphabetic order of prefixes ignored while selecting parent chain
penicillamine, (+/-)-
4-04-00-03228 (beilstein handbook reference)
unii-2xop7y1h98
2xop7y1h98 ,
valine, 3-mercapto
CCG-40247
penicilllamine
d-penicyllamine
3,3-dimethyl-l-cysteine
FT-0627604
FT-0624341
FT-0625502
3,3-dimethyl-dl-cysteine
.beta.-mercaptovaline
penicillamine, dl-
(+/-)-penicillamine
.beta.-thiovaline
penicillamine dl-form [mi]
3-mercapto-dl-valine
dl-dmc
S5962
AB00375988-03
SCHEMBL57527
smr000059161
MLS006011473
NC00476
DTXSID7044687
l-3-mercaptovaline
3-sulfanylvaline #
AB00052067_10
AB00052067_11
mfcd00004856
mfcd00064303
mfcd00064302
sr-05000001692
SR-05000001692-1
EN300-25364
SBI-0051475.P003
h-beta,beta-dimethyl-cys-oh;h-beta-mercapto-val-oh
HMS3714E05
CS-W018173
NCGC00018283-03
l-(+)-2-amino-3-mercapto-3-methylbutanoic acid |a,|a-dimethyl-l-cysteine
BCP24237
SY046568
VS-03708
Q27122242
(2r)-2-amino-3-methyl-3-sulfanylbutanoic acidl-beta,beta-dimethylcysteine
SY049414
AKOS016843630
AB87081
beta,beta-dimethyl-dl-cysteine, dl-2-amino-3-mercapto-3-methylbutanoic acid
2-amino-3-mercapto-3-methylbutanoicacid
SY045321
HY-W017457
Z203244248

Research Excerpts

Toxicity

The use of penicillamine in rheumatoid arthritis (RA) is limited by the incidence of adverse effects, some of which are potentially hazardous. Serum D-penicillamines levels were shown to be the same for patients who responded well to treatment and those who didn't.

ExcerptReferenceRelevance
"An unusual side effect on the skin after one year's high dosage (3,0 g/die) of D-Penicillamin-treatment is reported."( An unusual side effect on the skin under high dose D-penicillamin treatment.
Cegla, UH; Kroidl, RF,
)
0.13
"The use of penicillamine in rheumatoid arthritis (RA) is limited by the incidence of adverse effects, some of which are potentially hazardous."( Penicillamine in rheumatoid arthritis: adverse effects.
Hill, HF, 1979
)
0.26
"6 times their respective LD50 values in order to compare their relative effectiveness in prevention of death caused by exposure for 15 min to inhalation of nickel carbonyl (1."( Comparisons of antidotal efficacy of sodium diethyldithiocarbamate, D-penicillamine and triethylenetetramine upon acute toxicity of nickel carbonyl in rats.
Baselt, RC; Horak, E; Mitchell, J; Sunderman, FW, 1977
)
0.26
"A retrospective study of penicillamine toxicity in 156 patients yielded a high incidence of toxic reaction (62%), necessitating discontinuation of the drug therapy in 36% of the patients."( Toxicity of penicillamine. A serious limitation to therapy in rheumatoid arthritis.
Bernhard, GC; Goldman, AL; Halverson, PB; Kozin, F, 1978
)
0.26
"A family of four developed toxic blood levels of mercury after the mother vacuumed a spilled jar of liquid mercury from a closet in their apartment."( Toxicity of a family from vacuumed mercury.
Montiel, MM; Schwartz, JG; Snider, TE, 1992
)
0.28
" Toxicity is the chief reason for stopping treatment, the commonest adverse effects requiring cessation of therapy being proteinuria (10 to 13%), skin rashes (5 to 9%), gastrointestinal events (5%) and thrombocytopenia or leucopenia (2 to 5%)."( Penicillamine in rheumatoid arthritis. A problem of toxicity.
Samanta, A; Taylor, HG,
)
0.13
"After considering the cutaneous side effects of D-penicillamine in rheumatoid arthritis management, a few cases of cutaneous adverse reaction observed in 5 (13%) of 38 patients, who received the drugs, are described."( [Cutaneous side effects induced by D-penicillamine in the treatment of rheumatoid arthritis].
Baratelli, E; Broggini, M; Cappelli, A; Crespi, E; Filardi, PG; Volontè, S, 1990
)
0.28
"Six patients with histologically proven HBsAg-negative chronic active hepatitis (CAH), who were initially treated successfully with prednisolone with or without azathioprine, developed unacceptable adverse effects due to prednisolone."( D-penicillamine therapy in patients with HBsAg-negative chronic active hepatitis and major prednisolone-induced adverse effects.
Callender, ME; McClements, BM, 1990
)
0.28
" The minimising action of penicillamine as a chelating agent and/or lasix as a diuretic on the toxic side-effect of cisplatin was also studied."( Histopathological study into side-effect toxicity of some drugs used in treatment of cancer.
Afify, MM; el-Dieb, MK; el-Shazly, MO, 1989
)
0.28
" An in vivo study was made of the role played by--SH compounds in the antioxidant enzyme system involved in the detoxication of the LD50 of paraquat (PQ), and hence of their role in the detoxication of PQ."( Effects of various thiols on paraquat toxicity.
Barabás, K; Matkovics, B; Oroszlán, G; Szabó, L, 1986
)
0.27
"Many of the adverse reactions produced by penicillamine and other compounds with an active sulfhydryl group form a distinctive pattern when viewed as a class."( Adverse effects profile of sulfhydryl compounds in man.
Jaffe, IA, 1986
)
0.27
" Adverse effects occurred more frequently after rapid increases in dosage."( The toxicity of D-penicillamine in systemic sclerosis.
Blair, S; Medsger, TA; Steen, VD, 1986
)
0.27
" Toxic influences effect thrombo- and leukocytopenia (incidence 5-15%), gastrointestinal disturbances (10-30%), changes or loss of taste (5-30%), loss of hair (1-2%), and partly proteinuria (5-20%)."( [D-penicillamine--side effects, pathogenesis and decreasing the risks].
Grasedyck, K, 1988
)
0.27
" Use of D-penicillamine was associated with an adverse reaction in 28 cases (33%); transient leukopenia occurred in eight, rash in seven, transient platelet count depression in seven, enuresis in three, and abdominal pain in two."( Efficacy and toxicity of D-penicillamine in low-level lead poisoning.
Graef, J; Lovejoy, FH; Shannon, M, 1988
)
0.27
"Certain children who experience a toxic lead episode requiring hospitalization in infancy or early childhood will manifest central nervous system dysfunctions, including hyperactivity, as sequelae of this experience."( Chelation therapy in children as treatment of sequelae in severe lead toxicity.
Arcoleo, CG; Clark, J; David, OJ; Katz, S,
)
0.13
" There was no significant difference in overall outcome of the patients treated with D-penicillamine with respect to adverse effects, whether they had previous gold toxicity, previous gold therapy but no toxicity, or no previous gold therapy."( Prior gold therapy does not influence the adverse effects of D-penicillamine in rheumatoid arthritis.
Buchanan, WW; Howard-Lock, HE; Kean, WF; Lock, CJ, 1982
)
0.26
" The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine."( Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis.
Essigman, WK, 1982
)
0.26
"The incidence of penicillamine toxicity was determined in 250 patients who had never previously received gold, 76 patients who had received gold without toxic reaction, and 79 patients with a previous history of gold toxicity."( Influence of previous gold toxicity on subsequent development of penicillamine toxicity.
Smith, PJ; Stewart, IM; Swinburn, WR; Swinson, DR,
)
0.13
" Our findings explain a number of the toxic phenomena associated with D-penicillamine administration in RA."( D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3.
Emery, P; Huston, G; Idle, JR; Mitchell, SC; Panayi, GS; Shah, RR; Smith, RL; Waring, RH; Welsh, KI, 1984
)
0.27
"One hundred sixty-two consecutive patients with rheumatoid arthritis (RA) were studied for possible association between HLA antigens, particularly DR antigens, and disease characteristics and adverse reactions to gold or D-penicillamine treatment."( A systematic survey of HLA-A,B,C and D antigens and drug toxicity in rheumatoid arthritis.
Dequeker, J; Van Wanghe, P; Verdickt, W, 1984
)
0.27
"One hundred sixty-eight patients with rheumatoid arthritis treated with chloroquine (n = 87), gold salts (n = 133) and/or penicillamine (n = 77) were investigated for possible associations between HLA antigens and toxic reactions."( HLA antigens and toxicity to gold and penicillamine in rheumatoid arthritis.
Kolarz, G; Mayr, WR; Mayrhofer, F; Scherak, O; Smolen, JS; Thumb, NJ, 1984
)
0.27
" Serum D-penicillamine levels were shown to be the same for patients who responded well to treatment, those who did not respond, and for patients who had adverse side effects as well as those who had none."( D-penicillamine in patients with rheumatoid arthritis. Serum levels, pharmacokinetic aspects, and correlation with clinical course and side effects.
Ament, HJ; Henrichs, AM; Muijsers, AO; van de Stadt, RJ; van der Korst, JK, 1984
)
0.27
" All the silver compounds, including AgAc, produced a similar toxic syndrome with initial hyperexcitability, ataxia, central nervous depression, labored breathing, loss of righting reflex and death."( Acute toxicity of some silver salts of sulfonamides in mice and the efficacy of penicillamine in silver.
English, JP; Horner, HC; Roebuck, BD; Smith, RP, 1983
)
0.27
"The incidence of adverse reactions to D-penicillamine in 155 patients with rheumatoid arthritis was analysed and compared with their history of adverse reactions to gold."( Adverse reactions to D-penicillamine after gold toxicity.
Dodd, MJ; Griffiths, ID; Thompson, M, 1980
)
0.26
" The physician's approach to the management of side effects is therefore determined by the patient's response as well as by adverse reactions."( The side effects of penicillamine therapy in rheumatoid arthritis.
Huskisson, EC,
)
0.13
"Among 67 patients with rheumatoid arthritis treated with gold salts (aurothiopropanol sulphonate) a significant correlation (p less than 10(-2)) was noted between gold toxic reactions, whatever their type, and the HLA antigens A1, B8, Cw7, and DR3."( HLA system and side effects of gold salts and D-penicillamine treatment of rheumatoid arthritis.
Bardin, T; Dausset, J; Debeyre, N; Dryll, A; Legrand, L; Marcelli, A; Ryckewaert, A, 1982
)
0.26
" No reduction in efficacy or increase in serious adverse effects was present in this shared-care group."( Gold and penicillamine therapy: is shared care with general practitioners effective and safe?
Capell, HA; Hunter, JA; Pullar, T, 1982
)
0.26
" The decision to complete the therapeutic regimen despite an adverse reaction was justified by the striking clinical improvement."( Successful treatment of inorganic mercury neurotoxicity with N-acetyl-penicillamine despite an adverse reaction.
Markowitz, L; Schaumburg, HH, 1980
)
0.26
" Of 114 discontinued courses, 73 (27%) were due to adverse reactions."( Adverse effects of D-penicillamine in rheumatoid arthritis.
Atkins, CJ; Offer, RC; Patterson, AC; Robinson, HS; Stein, HB; Teufel, A, 1980
)
0.26
" Sixty-one patients developed 84 separate toxic reactions, 36 of which required drug withdrawal."( The toxicity pattern of D-penicillamine therapy. A guide to its use in rheumatoid arthritis.
Anastassiades, TP; Dwosh, IL; Ford, PM; Kean, WF; Kelly, HG, 1980
)
0.26
" These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine."( Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis.
Katz, WA; Rosenbaum, J; Schumacher, HR, 1980
)
0.26
"To determine whether intermittent rather than daily administration of D-penicillamine (D-Pen) would effectively reduce the incidence of adverse effects without significantly diminishing the clinical benefits."( Intermittent treatment with D-penicillamine is effective in lower doses and with fewer adverse effects in patients with rheumatoid arthritis.
Akahoshi, T; Hakoda, M; Kamatani, N; Kashiwazaki, S; Taniguchi, A, 1994
)
0.29
" The incidence of adverse effects was significantly lower in the intermittent group."( Intermittent treatment with D-penicillamine is effective in lower doses and with fewer adverse effects in patients with rheumatoid arthritis.
Akahoshi, T; Hakoda, M; Kamatani, N; Kashiwazaki, S; Taniguchi, A, 1994
)
0.29
"0 mM thiol, but is not seen at higher or lower drug concentrations; N-acetylcysteine (NAC) is toxic only at concentrations > or = 2 mM and shows no biphasic pattern; and glutathione (GSH) and penicillamine are only minimally toxic at all concentrations."( Mechanisms for the oxygen radical-mediated toxicity of various thiol-containing compounds in cultured mammalian cells.
Biaglow, JE; Held, KD, 1994
)
0.29
" Over a 2-yr period we have prospectively reviewed 114 patients with a suspected adverse cutaneous reaction to anti-rheumatic drugs."( Suspected cutaneous drug toxicity in rheumatoid arthritis--an evaluation.
Davis, MJ; Dawes, PT; Mattey, DL; Smith, AG; Wilkinson, SM, 1993
)
0.29
"Inclusion of sodium nitroprusside (Na2[Fe(2+)-(CN)5NO]) into the culture medium is toxic to cultured rat cerebellar granule neurons."( Inhibition of excitatory amino acid-induced phosphoinositide hydrolysis as a possible mechanism of nitroprusside neurotoxicity.
Chuang, DM; Yu, O, 1996
)
0.29
" In contrast, spermine/NO adduct (spermineNONOate) was shown to be more toxic under normoxic than under hypoxic conditions."( Enhanced release of nitric oxide causes increased cytotoxicity of S-nitroso-N-acetyl-DL-penicillamine and sodium nitroprusside under hypoxic conditions.
Bätz, M; De Groot, H; Ioannidis, I; Korth, HG; Paul, T; Sustmann, R, 1996
)
0.29
" These results demonstrate that (a) reduction in the availability of glucose and intracellular glutathione renders the cells more vulnerable to the cytotoxic effects of NO donors, (b) in this model of cytotoxicity, long-lived NO donors were more cytotoxic than short-lived NO donors, (c) the differential effects of N-acetylcysteine on S-nitroso-N-acetylpenicillamine-induced and bacterial lipopolysaccharide-mediated cytotoxicity support the existence of other toxic species different from NO or NO-related compounds with a potent cytotoxic activity in immunostimulated macrophages, and (d) other non-protein thiols like N-acetylcysteine may substitute for glutathione as a major component of the cellular antioxidant defense system."( The protective role of thiols against nitric oxide-mediated cytotoxicity in murine macrophage J774 cells.
Herman, AG; Matthys, KE; Zamora, R, 1997
)
0.3
" We conclude that exposures to toxic levels of NO cause prolonged disruption of [Ca2+]i homeostatic mechanisms, and that the resulting persistent [Ca2+]i elevations contribute to the delayed neurotoxicity of NO."( Disrupted [Ca2+]i homeostasis contributes to the toxicity of nitric oxide in cultured hippocampal neurons.
Brorson, JR; Zhang, H, 1997
)
0.3
" Monovalent nitrate mercury Hg(NO3)2 was more toxic than bivalent Hg(NO3)2."( Toxicity of organic and inorganic mercury to Saccharomyces cerevisiae.
Aoyama, I; Kungolos, A; Muramoto, S, 1999
)
0.3
"The results presented in this study indicate that the toxic response brought about by increasing concentrations of tert-butylhydroperoxide in CHP100 cells was mitigated significantly by exogenously added nitric oxide donors via a cyclic GMP-independent mechanism."( Different signalling pathways mediate the opposite effects of endogenous versus exogenous nitric oxide on hydroperoxide toxicity in CHP100 neuroblastoma cells.
Cantoni, O; Clementi, E; Guidarelli, A; Sciorati, C, 1999
)
0.3
" However, d-PCN is associated with a relatively high incidence of adverse effects when given in the standard dose of 25-30 mg/kg/d."( Adverse effects of reduced-dose d-penicillamine in children with mild-to-moderate lead poisoning.
Shannon, MW; Townsend, MK, 2000
)
0.31
" All adverse effects were transient and resolved during or immediately after chelation therapy."( Adverse effects of reduced-dose d-penicillamine in children with mild-to-moderate lead poisoning.
Shannon, MW; Townsend, MK, 2000
)
0.31
" Reduced-dose d-PCN also appears to be associated with a rate of adverse effects lower than previously reported; observed adverse effects appear to be benign and transient."( Adverse effects of reduced-dose d-penicillamine in children with mild-to-moderate lead poisoning.
Shannon, MW; Townsend, MK, 2000
)
0.31
" DMARDs that combine efficacy with negligible renal adverse effects should be used for the treatment of patients susceptible to DMARD-associated renal damage."( Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.
Schiff, MH; Whelton, A, 2000
)
0.31
"To evaluate rates on the adverse side effect and discontinuation of second-line drugs frequently used in the treatment of rheumatoid arthritis (RA)."( [Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs].
Jiang, L; Ni, L; Zhao, N, 2002
)
0.31
" Sulfasalazine users reported adverse events including upper abdominal trouble (39."( [Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs].
Jiang, L; Ni, L; Zhao, N, 2002
)
0.31
"Efforts have been made to minimize the toxic effect caused by beryllium."( Analysis of time-dependent recovery from beryllium toxicity following chelation therapy and antioxidant supplementation.
Johri, S; Sharma, P; Shrivastava, S; Shukla, S, 2004
)
0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" In conclusion, the present data suggest that both antioxidant systems, glutathione and trypanothione/trypanothione reductase, participate in protection of Leishmania against the toxic effect of nitrogen-derived reactive species."( Glutathione and the redox control system trypanothione/trypanothione reductase are involved in the protection of Leishmania spp. against nitrosothiol-induced cytotoxicity.
Cruz, AK; Cunha, FQ; Ferreira, SH; Fonseca, SG; Hothersall, JS; Moraes, RH; Noronha-Dutra, AA; Romão, PR; Tovar, J, 2006
)
0.33
" Zinc sulphate, aiming at the treatment of free-copper toxicosis, has emerged as effective, safe and cheap alternative."( Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap.
Sinha, S; Taly, AB, 2008
)
0.35
" There were no adverse effects."( Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap.
Sinha, S; Taly, AB, 2008
)
0.35
"Withdrawal of penicillamine from zinc sulphate/penicillamine maintenance therapy for patients with Wilson's disease was effective, safe and economic, for almost all patients."( Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap.
Sinha, S; Taly, AB, 2008
)
0.35
" No adverse effects were observed during chelation therapy."( Case series of mercury toxicity among children in a hot, closed environment.
Akyildiz, BN; Kondolot, M; Konuşkan, B; Kurtoğlu, S, 2012
)
0.38
" Our patient is one of three siblings on Penicillamine, she was the only one who developed massive breast enlargement four months after commencing Penicillamine therapy, as well as dermatological adverse reactions and myasthenia gravis three more months later."( Concurrent massive breast enlargement, myasthenia gravis and dermopathy as manifestations of penicillamine toxicity in a Wilson's disease patient.
Latif, SA; Poh, WY; Tan, SS, 2012
)
0.38
" Chelator-based treatment regimens were analyzed for their effect on neurologic and hepatic symptoms and for adverse events that led to discontinuation of therapy (Kaplan-Meier estimation; data were collected for a mean of 13."( Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Ferenci, P; Ferenci-Foerster, D; Gotthardt, DN; Hefter, H; Houwen, RH; Maieron, A; Merle, U; Reuner, U; Schäfer, M; Schmidt, HH; Stauber, R; Stremmel, W; Teufel, U; Thurik, F; Trocello, JM; Weiss, KH; Wiegand, F; Zoller, H, 2013
)
0.39
" Adverse events leading to discontinuation of treatment were more frequent among those receiving D-penicillamine than trientine (P = ."( Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Ferenci, P; Ferenci-Foerster, D; Gotthardt, DN; Hefter, H; Houwen, RH; Maieron, A; Merle, U; Reuner, U; Schäfer, M; Schmidt, HH; Stauber, R; Stremmel, W; Teufel, U; Thurik, F; Trocello, JM; Weiss, KH; Wiegand, F; Zoller, H, 2013
)
0.39
"Chelating agents are effective therapies for most patients with Wilson disease; D-penicillamine and trientine produce comparable outcomes, although D-penicillamine had a higher rate of adverse events."( Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Ferenci, P; Ferenci-Foerster, D; Gotthardt, DN; Hefter, H; Houwen, RH; Maieron, A; Merle, U; Reuner, U; Schäfer, M; Schmidt, HH; Stauber, R; Stremmel, W; Teufel, U; Thurik, F; Trocello, JM; Weiss, KH; Wiegand, F; Zoller, H, 2013
)
0.39
" The successful therapeutic uses of penicillamine have been hindered by its numerous adverse effects, both cutaneous and extra-cutaneous."( Penicillamine revisited: historic overview and review of the clinical uses and cutaneous adverse effects.
Abbas, O; Ishak, R, 2013
)
0.39
" During the treatment, clinical observations and 24-h urine copper excretion as well as adverse effects of medicines were recorded and analyzed."( Clinical efficacy and safety of chelation treatment with typical penicillamine in cross combination with DMPS repeatedly for Wilson's disease.
Chen, L; Fang, F; Li, XF; Liu, Y; Xu, SQ; Zhu, HY, 2013
)
0.39
"To evaluate medical treatments, in terms of adverse events (AEs) and therapeutic goals, in a large series of patients with cystinuria."( Adverse events associated with currently used medical treatments for cystinuria and treatment goals: results from a series of 442 patients in France.
Bataille, P; Bridoux, F; Brignon, P; Choquenet, C; Cochat, P; Combe, C; Conort, P; Courbebaisse, M; Daudon, M; Decramer, S; Doré, B; Dussol, B; Essig, M; Friedlander, G; Frimat, M; Gaunez, N; Jais, JP; Joly, D; Knebelmann, B; Le Toquin-Bernard, S; Lebbah, S; Lillo-Le Louët, A; Méjean, A; Meria, P; Morin, D; N'Guyen, HV; Normand, M; Pietak, M; Pontoizeau, C; Prot-Bertoye, C; Ronco, P; Saussine, C; Tostivint, I; Traxer, O; Tsimaratos, M, 2019
)
0.51
" However, associated adverse events (AEs) of D-pen treatment are frequent and often serious."( Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system.
Galindo, CL; Kim, JJ; Kumar, V; Singh, AP; Wheeler, N, 2021
)
0.62
" Food and Drug Administration Adverse Event Reporting System (FAERS) databases and calculated the reported odds ratio (ROR) with 95% confidence intervals (CI) using the disproportionality analysis."( Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system.
Galindo, CL; Kim, JJ; Kumar, V; Singh, AP; Wheeler, N, 2021
)
0.62
"BACKGROUND AND OBJECTIVE: There are limited data on the adverse events of D-penicillamine in Wilson's disease (WD) that can result in dose modification or treatment discontinuation."( Adverse Events with D-penicillamine Therapy in Hepatic Wilson's Disease: A Single-Center Retrospective Audit.
Darak, H; Giri, S; Gopan, A; Irtaza, M; Kale, A; Kumar, S; Patra, BR; Rao, PK; Shukla, A, 2022
)
0.72
" Adverse events (AEs) related to D-penicillamine treatment, the timing and management of these AEs were analysed."( Adverse Events with D-penicillamine Therapy in Hepatic Wilson's Disease: A Single-Center Retrospective Audit.
Darak, H; Giri, S; Gopan, A; Irtaza, M; Kale, A; Kumar, S; Patra, BR; Rao, PK; Shukla, A, 2022
)
0.72
" Overall, most common AEs were hematological [16, 57% (pancytopenia n = 8, bicytopenia n = 5 and hemolytic anemia n = 3)] while renal adverse events (n = 7, 25%) constituted the most common indication for permanent discontinuation."( Adverse Events with D-penicillamine Therapy in Hepatic Wilson's Disease: A Single-Center Retrospective Audit.
Darak, H; Giri, S; Gopan, A; Irtaza, M; Kale, A; Kumar, S; Patra, BR; Rao, PK; Shukla, A, 2022
)
0.72
" Temporary cessation of drug with reintroduction at a lower dose is an effective and safe option."( Adverse Events with D-penicillamine Therapy in Hepatic Wilson's Disease: A Single-Center Retrospective Audit.
Darak, H; Giri, S; Gopan, A; Irtaza, M; Kale, A; Kumar, S; Patra, BR; Rao, PK; Shukla, A, 2022
)
0.72
"Dysphagia has been reported as an adverse event for patients receiving rivastigmine for Alzheimer's disease (AD) treatment."( Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System.
Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022
)
0.72
"The purpose of this study was to determine the association between dysphagia and the usage of rivastigmine by using the pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS)."( Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System.
Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022
)
0.72
"When compared to patients prescribed donepezil, galantamine, or memantine, individuals prescribed rivastigmine were almost twice as likely to report dysphagia as an adverse event."( Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System.
Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022
)
0.72
"Patients prescribed rivastigmine were at greater risk of reporting dysphagia as an adverse event than patients prescribed many other medicines."( Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System.
Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022
)
0.72

Pharmacokinetics

The pharmacokinetic parameters of D-penicillamine were investigated by administering four intravenous bolus doses, four oral doses, and six constant rate intravenous infusions to a female mongrel dog at dosages comparable to 250, 500, 750, and 1000 mg.

ExcerptReferenceRelevance
"The pharmacokinetic effect of the combined treatment of penicillamine with indomethacin and chloroquine was investigated in patients with rheumatoid arthritis."( Pharmacokinetic interactions of penicillamine in rheumatoid arthritis.
Lindström, B; Seideman, P, 1989
)
0.28
"The pharmacokinetic disposition of D-penicillamine and its major metabolites, penicillamine cysteine disulfide ( PSSC ) and penicillamine disulfide ( PSSP ) has been studied in eight patients with rheumatoid arthritis."( Pharmacokinetics of the major metabolites of D-penicillamine in patients with rheumatoid arthritis.
Butler, M; Carruthers, G; Freeman, D; Harth, M; Rothwell, R; Weir, D, 1984
)
0.27
" After iv administration, plasma elimination half-life (T 1/2 beta) was 62."( The pharmacokinetics of D-penicillamine in man.
Carlson, GL; Dickson, ER; Go, VL; McPhaul, LW; Wiesner, RH,
)
0.13
"The pharmacokinetic parameters of D-penicillamine were investigated by administering four intravenous bolus doses, four oral doses, and six constant rate intravenous infusions to a female mongrel dog at dosages comparable to 250, 500, 750, and 1000 mg in man."( The pharmacokinetics of penicillamine in a female mongrel dog.
Bergstrom, RF; Kay, RD; Wagner, JG, 1981
)
0.26
" Pharmacokinetic factors may partially explain these clinical observations."( Clinical pharmacokinetics of slow-acting antirheumatic drugs.
Tett, SE, 1993
)
0.29
" Response to therapy can be variable, and there is a lack of pharmacokinetic information available for dogs."( Pharmacokinetics and relative bioavailability of D-penicillamine in fasted and nonfasted dogs.
Bailie, MB; Buchweitz, JP; Hauptman, JG; Johnson, MB; Kruger, JM; Langlois, DK; Lehner, AF; Ross, DE; Schall, WD,
)
0.13
" Pharmacokinetic parameters were calculated for each dog."( Pharmacokinetics and relative bioavailability of D-penicillamine in fasted and nonfasted dogs.
Bailie, MB; Buchweitz, JP; Hauptman, JG; Johnson, MB; Kruger, JM; Langlois, DK; Lehner, AF; Ross, DE; Schall, WD,
)
0.13
" Mean area under the plasma concentration curve ± SD was 16."( Pharmacokinetics and relative bioavailability of D-penicillamine in fasted and nonfasted dogs.
Bailie, MB; Buchweitz, JP; Hauptman, JG; Johnson, MB; Kruger, JM; Langlois, DK; Lehner, AF; Ross, DE; Schall, WD,
)
0.13
" It is therefore of significant practicality to understand the pharmacokinetic (PK) parameters of chelating agents, particularly since they are oftentimes quite expensive."( Liquid chromatography/tandem mass spectrometric analysis of penicillamine for its pharmacokinetic evaluation in dogs.
Buchweitz, JP; Dirikolu, L; Johnson, M; Langlois, DK; Lehner, AF, 2020
)
0.56

Compound-Compound Interactions

The aim of this study was to assess the clinical efficacy and safety of chelation treatment with penicillamine (PCA) in cross combination with sodium 2, 3-dimercapto-1-propane sulfonate.

ExcerptReferenceRelevance
"The efficacy of azathioprine, methotrexate, cyclosporin, and d-penicillamine alone and in combination with chloroquine was quantitated in an in vitro system, with the use of mitogen-stimulated human peripheral blood mononuclear cells."( Synergistic and additive effects of disease modifying anti-rheumatic drugs combined with chloroquine on the mitogen-driven stimulation of mononuclear cells.
de Vreede, TM; de Vries, E; Dijkmans, BA,
)
0.13
" Open non-randomised uncontrolled studies have shown that antimalarials combined with cytotoxic agents are effective but highly toxic."( The use of antimalarials in combination with other disease modifying agents in RA--the British experience.
Capell, HA; Duncan, MR, 1996
)
0.29
"The aim of this study was to assess the clinical efficacy and safety of chelation treatment with penicillamine (PCA) in cross combination with sodium 2, 3-dimercapto-1-propane sulfonate (DMPS) repeatedly in patients with Wilson's disease (WD)."( Clinical efficacy and safety of chelation treatment with typical penicillamine in cross combination with DMPS repeatedly for Wilson's disease.
Chen, L; Fang, F; Li, XF; Liu, Y; Xu, SQ; Zhu, HY, 2013
)
0.39
" In conclusion, WD patients with a single R778L heterozygote mutation can present with ALF as the initial clinical manifestation, and intermittent plasma transfusion combined with chelating therapy may alleviate fulminant WD without LT or ALS."( Plasma transfusion combined with chelating therapy alleviates fulminant Wilson's disease with a single Arg778Leu heterozygote mutation.
Gong, Q; Liu, J; Liu, L; Shen, H; Xue, Y; Zhang, H,
)
0.13

Bioavailability

The relative bioavailability of D-penicillamine was determined after single 500 mg oral doses of commercial tablets to healthy male volunteers under fasting and nonfasting conditions. Urinary excretion of the collagen-specific amino acids hydroxyproline and hydroxylysine, and of proline was used as a guideline.

ExcerptReferenceRelevance
" The beneficial effects of methionine may be attributed to its ability to increase the bioavailability of glutathione (GSH), useful in chelating Pb and counter-acting the toxic effects, as evidenced by restoration of the Pb-induced decrease in hepatic GSH level by treatment with methionine."( Influence of methionine supplementation in chelation of lead in rats.
Kachru, DN; Khandelwal, S; Tandon, SK, 1989
)
0.28
" Urinary excretion of the collagen-specific amino acids hydroxyproline and hydroxylysine, and of proline was used as a guideline for monitoring the bioavailability of D-penicillamine."( The progress of oesophageal involvement in progressive systemic sclerosis during D-penicillamine treatment.
Aggestrup, S; Hendel, L; Stentoft, P, 1989
)
0.28
" A preliminary bioavailability study of two of the lead structures is presented."( Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.
Blythin, DJ; Bober, LA; Chiu, PJ; Conn, DJ; Domalski, MS; Kaminski, JJ; Solomon, DM; Spitler, J; Verbiar, LL; Wong, SC, 1986
)
0.27
" Its bioavailability is also dramatically decreased in patients with malabsorption states."( Clinical pharmacokinetics of D-penicillamine.
Bannwarth, B; Netter, P; Nicolas, A; Péré, P, 1987
)
0.27
"The bioavailability of D-penicillamine was measured in 24 patients with generalized scleroderma (Progressive Systemic Sclerosis, PSS)."( Bioavailability of D-penicillamine in relation to gastrointestinal involvement of generalized scleroderma.
Ammitzbøll, T; Asboe-Hansen, G; Hendel, L; Kreuzig, F, 1987
)
0.27
" D-penicillamine bioavailability was examined after oral, duodenal, intravenous and rectal administration."( Bioavailability of D-penicillamine in a patient with gastrointestinal progressive systemic sclerosis.
Ammitzbøll, T; Asboe-Hansen, G; Hendel, L; Kreuzig, F; Worning, H, 1986
)
0.27
" Relative bioavailability of the enteric-coated tablet was found to be 67% when compared with the uncoated tablet."( Development and evaluation of enteric-coated penicillamine tablets.
Chambliss, DA; Chambliss, WG; Cleary, RW; Harland, EC; Jones, AB; Kibbe, AH, 1984
)
0.27
"The absolute and the relative bioavailability of D-penicillamine, available from different dosage forms and products, was studied in 10 healthy volunteers."( Bioavailability and pharmacokinetics of D-penicillamine.
Beubler, E; Kreuzig, F; Kukovetz, WR; Moritz, AJ; Nirnberger, G; Werner-Breitenecker, L, 1983
)
0.27
"The relative bioavailability of D-penicillamine was determined after single 500 mg oral doses of commercial tablets to healthy male volunteers under fasting and nonfasting conditions."( Influence of food on the bioavailability of penicillamine.
Osman, MA; Patel, RB; Schuna, A; Sundstrom, WR; Welling, PG, 1983
)
0.27
" Its bioavailability is variable and may decrease by as much as 70% in the presence of food, antacids and iron salts."( Clinical pharmacokinetics of slow-acting antirheumatic drugs.
Tett, SE, 1993
)
0.29
" In the present study, we investigated the absorption-enhancing effects of an NO donor, 3-(2-hydroxy-1-methylethyl-2-nitrosohydrazino)-N-methyl-1-propa namine (NOC7), on drugs that are poorly absorbed from the gastrointestinal tract."( Improvement of intestinal absorption of macromolecules by nitric oxide donor.
Matsumoto, M; Mayumi, T; Mizuno, N; Numata, N; Takahashi, K; Utoguchi, N; Watanabe, Y, 2000
)
0.31
" Our results demonstrated that membranes influence bioavailability of reactive nitrogen species and bias the activity of different S-nitrosothiols."( Influence of nitric oxide donors on the intrinsic fluorescence of Na+,K+-ATPase and effects on the membrane lipids.
de Lourdes Barriviera, M; Fontes, CF; Hassón-Voloch, A; Louro, SR, 2005
)
0.33
" It has been demonstrated, however, that copper augments the inhibitory effect of homocysteine on nitric oxide (NO)-mediated relaxation of the rat aorta through increased superoxide formation, which reacts with NO thereby reducing the bioavailability of NO."( Penicillamine administration reverses the inhibitory effect of hyperhomocysteinaemia on endothelium-dependent relaxation and superoxide formation in the aorta of the rabbit.
Angelini, GD; Jeremy, JY; Jones, RA; Koupparis, A; Persad, R; Shukla, N, 2006
)
0.33
" Copper is a catalyst for the generation of H2O2 in the presence of homocysteine and in the presence of copper, H2O2 undergoes reactions resulting in the generation of O2*-, which reacts with NO to produce peroxynitrite (ONOO-), thereby reducing the bioavailability of NO and impairing NO-mediated relaxation of CC."( Penicillamine administration reverses the inhibitory effect of hyperhomocysteinaemia on endothelium-dependent relaxation in the corpus cavernosum in the rabbit.
Angelini, G; Jeremy, J; Koupparis, AJ; Persad, R; Shukla, N, 2006
)
0.33
"Coadministration of d-penicillamine with food decreases relative bioavailability and maximum plasma drug concentrations (C(max)) in dogs."( Pharmacokinetics and relative bioavailability of D-penicillamine in fasted and nonfasted dogs.
Bailie, MB; Buchweitz, JP; Hauptman, JG; Johnson, MB; Kruger, JM; Langlois, DK; Lehner, AF; Ross, DE; Schall, WD,
)
0.13
" There were significant reductions in relative bioavailability and C(max) in fed dogs (P < ."( Pharmacokinetics and relative bioavailability of D-penicillamine in fasted and nonfasted dogs.
Bailie, MB; Buchweitz, JP; Hauptman, JG; Johnson, MB; Kruger, JM; Langlois, DK; Lehner, AF; Ross, DE; Schall, WD,
)
0.13
" Endothelial dysfunction and poor NO bioavailability are hallmarks of vasculature dysfunction in states of insulin resistance and metabolic syndrome (MetSyn)."( Blunted flow-mediated responses and diminished nitric oxide synthase expression in lymphatic thoracic ducts of a rat model of metabolic syndrome.
Gasheva, O; Muthuchamy, M; Zawieja, DC; Zawieja, SD, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

D-penicillamine at the dosage we used is not effective in the treatment of primary biliary cirrhosis and is associated with a high incidence of serious side effects. Total withdrawals were significantly higher in the moderate and high dosage groups (OR=1.5) The disappearance of anti-DNA antibodies after reducing the dosage of D-Penicillamines or withdrawal of therapy is an argument in favour of the inducing role of the drug.

ExcerptRelevanceReference
" Doubling the dosage for 3 days induced a further drop in transferrin and ceruloplasmin."( [Serum levels of alpha-2-macroglobulin, ceruloplasmin, transferrin, alpha-1-antitrypsin and complement (beta-1-C) before and following 3- and 6-day injections of D-penicillamine in man].
Cegla, UH,
)
0.13
"The effects of different antirheumatic drugs administered according to various dosing regimes on tuberculin hypersensitivity in rats have been assessed quantitating the changes of exudate volume and mononuclear cells immigration at the site of challenge."( Delayed hypersensitivity to tuberculin in rats: effects of antirheumatic drugs.
Arrigoni-Martelli, E; Binderup, L; Bramm, E, 1979
)
0.26
" Since EDTA is excreted much like creatinine, the dosage must be reduced proportionately in response to elevated serum creatinine levels in the patient with renal failure."( Chelation therapy in lead nephropathy.
Morgan, JM, 1975
)
0.25
"An unusual side effect on the skin after one year's high dosage (3,0 g/die) of D-Penicillamin-treatment is reported."( An unusual side effect on the skin under high dose D-penicillamin treatment.
Cegla, UH; Kroidl, RF,
)
0.13
" At identical doses D-penicillamine had a significantly stronger enhancing effect than the 8-hydroxyquinoline derivate, except for the highest dosage which was 100 mg daily."( Effects of penicillamine and hydroxyquinoline on absorption of orally ingested 65zinc in the rat.
Knudsen, L; Weismann, K, 1978
)
0.26
" In all the patients included in this study, dosage had exceded 1,600 rets."( [Plexus lesions following radiation therapy. Report of nineteen cases (author's transl)].
Contamin, F; Ecoffet, M; Jouneau, P; Mignot, B; Ollat, H,
)
0.13
" The cells show a diminished sensitivity to D-Pen added after 24 hours in culture, although the dose-response relationship is maintained."( The inhibitory effect of D-penicillamine on human lymphocyte cultures stimulated by phytohaemagglutinin, the antagonistic action of L-cysteine and synergistic inhibition by copper sulphate.
Maini, RN; Roffe, L; Room, G, 1979
)
0.26
" Its indications in the therapy of RA were defined, and current principles of dosage were presented."( Penicillamine in rheumatoid arthritis: clinical pharmacology and biochemical properties.
Jaffe, IA, 1979
)
0.26
" After subsidence of the exudative stages of pulmonary fibrosis the glucocorticoids should be, in our opinion, gradually reduced, so that a D-penicillamine therapy of a smaller dosage can also be efficient."( Penicillamine in the treatment of pulmonary fibrosis.
Bröll, H; Eberl, R, 1979
)
0.26
" Reduction in steroid dosage was considerable and was greater than half the mean pretreatment dose after two years but the absence of a control group makes the full significance of these uncertain."( Difficulties in the use of D-penicillamine in the treatment of rheumatoid arthritis.
Barraclough, D; Kincaid-Smith, P; Macdonald, I; Muirden, KD; Richter, D; Stockman, A, 1979
)
0.26
" Therefore it is better to combine glucocorticoids and azathioprine in some cases, especially in those with a high dosed glucocorticoid therapy."( [Therapy of chronic hepatitis (author's transl)].
Siede, W, 1979
)
0.26
" The main task has been seen to be the exploration of various dosage schedules in the hope of finding an effective dose which does not produce a high incidence of adverse effect."( Penicillamine in rheumatoid arthritis.
Hill, AG; Hill, HF, 1979
)
0.26
" These data indicate that D-PeA is not capable of producing VB6 deficiency in the dosage employed in patients."( [Effect of D-penicillamine on vitamine B6 and collagen metabolism (author's transl)].
Kajiwara, T, 1979
)
0.26
" Despite use of a high dosage regimen, such as has evoked intolerable side effects in a high percentage of patients with rheumatoid arthritis, we have experienced few side effects in a total of 48 patients suffering from diseases with auto-immune components, a finding we speculate is due to replacement of nutrients inactivated or removed by D-penicillamine, and to supplementation with selected nutrients."( Pilot study of d-penicillamine, vitamins and minerals in multiple sclerosis.
Alba, A; Berger, AR; Rudez, A; Seelig, MS; Tarlau, M, 1978
)
0.26
" There were no identifiable lasting effects of this dosage on cobalt, selenium and particularly zinc content."( [The effect of D-penicillamine on the trace elements in rat organs (author's transl)].
Kollmer, WE; Schramel, P; Weiner, C, 1979
)
0.26
"A comparison of two series of patients with rhe,matic polyarthritis, the one (n = 140) treated with dosage equal to or higher than 900 mg, the other (n = 60) with dosage between 600 and 750 mg, did not reveal significant difference in clinical and biological efficacy."( [Study of optimal posology of penicillamine in the treatment of common rheumatoid polyarthritis (apropos of a personal series of 200 cases)].
Camus, JP; Crouzet, J; Leca, AP; Prier, A, 1977
)
0.26
" Intra-articular injection of this substance at a dosage of 5 to 250 mg is followed by an inhibition of protein synthesis in the synovial fluid cells."( [Mode of action of D-penicillamine in chronic polyarthritis. 1. Protein synthesis inhibition in synovial fluid cells].
Altmann, H; Bröll, H; Kocsis, R; Tausch, G,
)
0.13
" A relatively high dosage resulted in a reduction of the cytinuria."( [Cystine stone therapy with mercapto-propyonyl-glycine (MPG) (Thiola) (author's transl)].
Stuhlsatz, HW; Terhorst, B, 1975
)
0.25
"Red cell aplasia developed in a case of Wilson's disease following an increase in D-penicillamine dosage after 14 years' treatment."( Red cell aplasia following prolonged D-penicillamine therapy.
Gollan, JL; Hoffbrand, AV; Hussein, S; Sherlock, S, 1976
)
0.26
" The smaller dosage of D-penicillamine did not effect the collagen synthesis in skin or bone."( [Mode of action of D-penicillamine on collagen metabolism].
Trnavská, Z; Trnavský, K,
)
0.13
" It is concluded that penicillamine at low dosage is an unreliable chelator of gold salts in vivo and its use in the management of gold toxicity remains speculative."( Interaction of D-penicillamine with gold salts: in vivo studies on gold chelation and in vitro studies on protein binding.
Barraclough, D; Davis, P,
)
0.13
"Mice dosed with methylmercury chloride (0."( The effect of oral doses of a polythiol resin on the excretion of methylmercury in mice treated with cysteine, D-penicillamine or phenobarbitone.
Clarkson, TW; Magos, L, 1976
)
0.26
" Dosing with D-penicillamine (25 mg/kg) and levamisole (5 mg/kg) at the time of challenge produced a significant enhancement of the reaction."( Pertussis vaccine pleurisy: a model of delayed hypersensitivity.
Arrigoni-Martelli, E; Dieppe, PA; Huskisson, EC; Willoughby, DA, 1976
)
0.26
" 3 DMSA was effective in decreasing body burden and the brain concentration of Hg in rats dosed orally with methylmercury (MeHgCl) when intraperitoneal treatment started with 40 mg/kg DMSA 24 h after Hg."( The effects of dimercaptosuccinic acid on the excretion and distribution of mercury in rats and mice treated with mercuric chloride and methylmercury chloride.
Magos, L, 1976
)
0.26
" Dose-response analysis indicated that L-NNA was 87 and 230 times more potent than L-NMA and L-NAA, respectively."( Comparison of the inhibitory potencies of N(G)-methyl-, N(G)-nitro- and N(G)-amino-L-arginine on EDRF function in the rat: evidence for continuous basal EDRF release.
Chaudhuri, G; Cuevas, JM; Ignarro, LJ; Vargas, HM, 1991
)
0.28
" Three and 24 hr after the end of the infusion, each rabbit was anesthetized with pentobarbital and instrumented to monitor blood pressure, and dose-response curves were performed using SNAP or GTN."( Lack of tolerance to a 24-hour infusion of S-nitroso N-acetylpenicillamine (SNAP) in conscious rabbits.
Chern, WH; Han, BJ; Lee, FW; Shaffer, JE, 1992
)
0.28
" SK&F S-106203 produced dose-dependent rightward shifts in the LTC4 and LTE4 dose-response curves."( SK&F S-106203 inhibits leukotriene C4, leukotriene D4 and leukotriene E4 vasopressor responses in the conscious rat.
Eckardt, RD; Egan, JW; Newton, JF; Slivjak, MJ; Smith, EF, 1990
)
0.28
" The dosage of D-penicillamine ranged from 250-1000 mg/d (mean = 750 mg); that of methotrexate ranged from 5-15 mg/week (mean = 10 mg)."( Combination D-penicillamine and methotrexate therapy: proposal for early and aggressive treatment for rheumatoid arthritis.
Lee, S; Solomon, G, 1990
)
0.28
" The plasma pharmacokinetics of D-penicillamine (D-pen) and D-penicillamine-albumin disulphide (D-pen-alb) were examined over a dosage interval in six patients with rheumatoid arthritis."( D-penicillamine and D-penicillamine-protein disulphide in plasma and synovial fluid of patients with rheumatoid arthritis.
Day, RO; Joyce, DA, 1990
)
0.28
" Before dosing with D-penicillamine, the median 24 h urinary bismuth output was 55 micrograms 24 h-1 (range 17-156 micrograms 24 h-1) and following dosing with D-penicillamine the median 24 h urinary bismuth output was 53 micrograms 24 h-1 (range 12-156 micrograms 24 h-1)."( D-penicillamine does not increase urinary bismuth excretion in patients treated with tripotassium dicitrato bismuthate.
Nwokolo, CU; Pounder, RE, 1990
)
0.28
" Only after drastic reduction of the penicillamine dosage to 600 mg three times daily was there any improvement and after 11 weeks the patient was again able to walk and was discharged."( [Wilson's disease--critical deterioration under high-dose parenteral penicillamine therapy].
Bauer, J; Druschky, KF; Hilz, MJ; Neundörfer, B; Schuierer, G, 1990
)
0.28
" When rabbits were daily injected intravenously with D-Pen at the per kilogram dosage administered to rheumatoid patients, neovascularization as quantitated by the proliferation of corneal new blood vessels was significantly inhibited."( Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine.
Hirohata, K; Matsubara, T; Saura, R; Ziff, M, 1989
)
0.28
" It is probably partly connected with the dosage of D-penicillamine which was used."( Clinical application of D-penicillamine in ankylosing spondylitis: a 9-month study.
Bernacka, K; Sierakowski, S; Tytman, K,
)
0.13
" During gradual reduction of the steroid dosage osteocalcin returned to pretreatment values."( Serum osteocalcin in rheumatoid arthritis and other inflammatory arthritides: relation between inflammatory activity and the effect of glucocorticoids and remission inducing drugs.
Ekenstam, EA; Hällgren, R; Ljunghall, S, 1986
)
0.27
" Reduction in dosage is recommended when surgery is planned to increase collagen formation and, thus, healing."( Management of an oroantral fistula in a patient with Wilson's disease: case report and review of the literature.
Alley, RS; Greene, MW; King, RC, 1988
)
0.27
"The present paper reviews the different therapeutic uses of D-penicillamine and outlines the dosage regimen of D-penicillamine for treatment of rheumatoid arthritis."( [D-penicillamine--a current review of areas of use and dosage guidelines].
Sörensen, H, 1988
)
0.27
" These results suggest that in the dosage regimen used, auranofin is safer than D-penicillamine but that D-penicillamine tends to show greater clinical effectiveness in patients with rheumatoid arthritis."( Auranofin or D-penicillamine in the treatment of rheumatoid arthritis.
Hochberg, MC, 1986
)
0.27
" Dose-response curves showed that Aur was at least 10 times more potent than GST."( Comparison of the effects of auranofin, gold sodium thiomalate, and penicillamine on resorption of cultured fetal rat long bones.
Hurley, MM; Jones, TG; Raisz, LG; Vargas, SJ, 1987
)
0.27
" However, in the presence of copper sulfate, captopril inhibited the NK activity in a dose-response fashion."( Immunosuppression by captopril in vitro: inhibition of human natural killer activity by copper-dependent generation of hydrogen peroxide.
Iwata, M; Maruyama, M; Sugiyama, E; Yamashita, N; Yano, S; Yoshikawa, T, 1986
)
0.27
" With vitamin E as adjunct therapy, the dosage level of penicillamine could be lowered by 50%, thereby minimizing side effects."( Interactions of vitamin E and penicillamine in the treatment of hereditary avian muscular dystrophy.
Brandon, S; Dement, SH; Hill, EJ; Park, CR; Park, JH; Serafin, WE, 1987
)
0.27
" The daily dosage of D-penicillamine never exceeded 600 mg."( [3 cases of obliterating bronchiolitis during treatment of rheumatoid polyarthritis with D-penicillamine].
Bontoux-Carre, E; Racineux, JL; Renier, JC, 1986
)
0.27
" Whatever the reason for the suspension of treatment, it was not influenced by the history of the rheumatoid arthritis, the rheumatoid serology, the sex of the patient or the maximal dosage of D-penicillamine."( [D-penicillamine in the treatment of rheumatoid polyarthritis. 104 cases with a 5-year follow-up].
Chantreuil, C; Eveleigh, MC; Fouquet, B; Lalot, F; Valat, JP, 1986
)
0.27
" The dosage is generally 600 mg per day, with a maximum dosage of 900 mg per day."( [Surveys of the epidemiological team of the French Rheumatology Society (RESFR) on the prescription of D-penicillamine in the treatment of rheumatoid polyarthritis].
Carter, H; Chevallier, J; Ghoussoub, K; Paolaggi, JB, 1986
)
0.27
" The duration and dosage of the treatment are not involved."( [Myasthenia induced by D-penicillamine during the treatment of rheumatoid polyarthritis].
Carter, H; Delrieu, F; Job-Deslandre, C; Kahan, A; Menkès, CJ, 1986
)
0.27
" In practice, however, it has been found that prohibitively extensive numbers of animals and laboratory services are required to establish drug efficacy, safety, and dosage regimes."( Models for assessing scar tissue inhibitors.
Constable, IJ; Martin, CE; van Bockxmeer, FM,
)
0.13
" To reduce the physiological alterations induced by NSAIDs, short-half-life drugs such as ibuprofen, flurbiprofen or ketoprofen should be used at the maximally tolerable dosage interval."( Antirheumatic medication in pregnancy.
Brooks, PM; Needs, CJ, 1985
)
0.27
" In practice, however, it has been found that prohibitively extensive numbers of animals and laboratory services are required to establish drug efficacy, safety, and dosage regimes."( Models for assessing scar tissue inhibitors.
Constable, IJ; Martin, CE; van Bockxmeer, FM,
)
0.13
" The dosage depends, however, on individual factors not yet well understood, and we recommend restriction of its use to patients who do not tolerate D-penicillamine well."( Oral zinc sulphate for Wilson's disease.
Bouquet, J; Degenhart, HJ; Sinaasappel, M; Van Caillie-Bertrand, M; Visser, HK, 1985
)
0.27
" The types of cutaneous manifestations may, in some instances, be correlated with the disease being treated and the dosage and duration of penicillamine therapy."( Penicillamine: review and cutaneous manifestations.
Alter, JN; Fisher, M; Levy, RS, 1983
)
0.27
" Enteric-coated penicillamine tablets were tested in vivo in nine weanling pigs divided into three groups: a negative control group, a test group dosed with enteric-coated penicillamine tablets, and a positive control group dosed with uncoated tablets."( Development and evaluation of enteric-coated penicillamine tablets.
Chambliss, DA; Chambliss, WG; Cleary, RW; Harland, EC; Jones, AB; Kibbe, AH, 1984
)
0.27
" The disappearance of anti-DNA antibodies after reducing the dosage of D-Penicillamine (1 case) or withdrawal of therapy (2 cases) is an argument in favour of the inducing role of the drug."( [Lupus biology: incidence and development in 84 rheumatoid polyarthritis patients treated with D-penicillamine].
Bisson, M; Clerc, D; Massias, P; Sallière, D; Segond, P, 1984
)
0.27
" Dosage by liquid phase chromatography enables study of intestinal absorption, reduced by meals, the distribution made according to a 2 compartment model, urinary and faecal excretion."( [Pharmacology and mechanism of action of D-penicillamine in rheumatoid polyarthritis].
Bisson, M; Clerc, D; Massias, P; Sallière, D, 1983
)
0.27
" In addition to numerous qualitative methodologic deficiencies, many studies showed inadequacies in sample size and duration of treatment, and the drug dosage used varied from one study to another."( Does drug therapy slow radiographic deterioration in rheumatoid arthritis?
Dawson, N; Iannuzzi, L; Kushner, I; Zein, N, 1983
)
0.27
" Three to eight weeks after D-penicillamine administration in a dosage of 20 to 50 mg per day, 73% of Brown Norway (BN) rats became ill."( Effects of prolonged administration of D-penicillamine or captopril in various strains of rats. Brown Norway rats treated with D-penicillamine develop autoantibodies, circulating immune complexes, and disseminated intravascular coagulation.
Andres, GA; Brentjens, JR; Donker, AJ; Venuto, RC; Vladutiu, AO, 1984
)
0.27
"Carboxy-labeled 14C-D-penicillamine was prepared and dosed at 50 mg/kg to Sprague-Dawley rats kept in metabolism cages."( Study on in vivo decarboxylation of D-penicillamine in rats.
Kucharczyk, N; Sofia, RD; Wong, KK; Yang, JT, 1984
)
0.27
" The effects were compared with those observed when the same dosage was started at the onset of the granulation tissue formation and with pair-fed controls."( Effect of D-penicillamine pre- and post-implantation treatment on formation of sponge-induced granulation tissue in rats.
Helin, G; Junker, P; Lorenzen, I, 1984
)
0.27
" With a dosage of 750 mg/day, basic serum levels of 100 microM are gradually reached."( D-penicillamine in patients with rheumatoid arthritis. Serum levels, pharmacokinetic aspects, and correlation with clinical course and side effects.
Ament, HJ; Henrichs, AM; Muijsers, AO; van de Stadt, RJ; van der Korst, JK, 1984
)
0.27
" The dosage and the duration of treatment as they relate to the induction of cleft palate were also studied."( D-penicillamine-induced cleft palate in mice.
Myint, B, 1984
)
0.27
" Non-steroidal anti-inflammatory drugs in full dosage should always be the first choice of treatment."( Medical management of rheumatoid arthritis with emphasis on the Western Pacific Region.
Muirden, KD, 1983
)
0.27
" The over-all approach to the use of the drug, including currently accepted methods of dosing and safety monitoring, is reviewed."( Penicillamine: an anti-rheumatoid drug.
Jaffe, IA, 1983
)
0.27
" With patients on established penicillamine regimes, the concentration of free penicillamine in the plasma has been found to vary between 4 and 20 microM depending on dosage and time of administration."( Methods for assaying D-penicillamine in a clinical setting.
Crawhall, JC, 1984
)
0.27
" Further downward adjustment of currently used daily dose, though desirable because of the relationship between dosage and side effects, seems doomed by unacceptable loss of therapeutic efficacy in most cases."( Low-dose penicillamine treatment of RA. Comparison of 600 mg and 300 mg regimens.
Mäkisara, P; Nissilä, M; Nuotio, P; von Essen, R, 1982
)
0.26
" Withdrawals could be reduced by lowering dosage and making increments extremely slowly."( Penicillamine in rheumatic diseases: a prospective study of tolerance and efficacy.
Kåss, E; Munthe, E,
)
0.13
") inhibited AA in the same dosing regimen."( [Studies of D-penicillamine (5): effects on rat adjuvant arthritis (author's transl)].
Higuchi, S; Kimura, M; Nakaike, S; Ohzeki, M; Otomo, S; Sasajima, M; Tarumoto, Y, 1981
)
0.26
"The absolute and the relative bioavailability of D-penicillamine, available from different dosage forms and products, was studied in 10 healthy volunteers."( Bioavailability and pharmacokinetics of D-penicillamine.
Beubler, E; Kreuzig, F; Kukovetz, WR; Moritz, AJ; Nirnberger, G; Werner-Breitenecker, L, 1983
)
0.27
" Reduction of penicillamine dosage is desirable to prevent complications, but this is accompanied by an increase of cystine excretion."( Experience with penicillamine in the treatment of cystinuria.
Crawhall, JC,
)
0.13
" Rash is uncommon, and hematologic problems are relatively few; both usually respond to dosage alterations."( Penicillamine in chronic arthritis of childhood.
Ansell, BM; Hall, MA,
)
0.13
" The type and incidence of side effects depend on the original disease and on penicillamine dosage and duration of treatment."( Penicillamine-induced skin lesions.
Fisher, M; Scheinberg, IH; Sternlieb, I,
)
0.13
" Experience with different dosage regimes of levamisole suggest that 150 mg weekly is the optimal dose."( Treatment of rheumatoid arthritis with levamisole.
Huskisson, EC, 1980
)
0.26
" We conclude that D-penicillamine at the dosage we used is not effective in the treatment of primary biliary cirrhosis and is associated with a high incidence of serious side effects."( A prospective trial of D-penicillamine in primary biliary cirrhosis.
Alpert, E; Kaplan, MM; Matloff, DS; Resnick, RH, 1982
)
0.26
"Tissue copper levels of brindled (Mobr) mice and normal litter-mates after single and repeated dosing with CuCl2 and/or D-penicillamine are examined, together with a study of the cytosol distribution of copper after CuCl2 treatment."( The distribution of copper in neonatal mottled mutant mice after exposure to copper and penicillamine.
Hunt, DM; Port, AE, 1982
)
0.26
" In therapeutic dosage it will adequately control joint symptoms in the majority of patients."( Pharmacotherapy of juvenile rheumatoid arthritis.
Lindsley, CB, 1981
)
0.26
" In several controlled clinical studies, DPA-therapy has been shown to be effective, even in lower dosage (450--600 mg/day) than used in first years after introduction of this drug."( [Current status of D-penicillamine therapy in chronic polyarthritis].
Franke, M; Menning, H; Ströbel, G,
)
0.13
"Tiopronin (50 mg/kg) and D-penicillamine (50 mg/kg) do not exhibit anti-inflammatory effects in classic animal models (carragenin oedema, granuloma cotton pellets) but suppress pertussis vaccine oedema, an immunological model, when given with a long-lasting dosing regime."( Some pharmacological properties of tiopronin.
Capasso, F, 1981
)
0.26
" The dose of the drug was on average, 1 gram daily, which, in one series of patients, was administered at the start of treatment and in another series, with an increase of dosage of 250 mg every 20 days."( [Tiopronine: new basic treatment for rheumatoid arthritis. Open study of 158 cases].
Barbieri, P; Ciompi, ML; Colamussi, V; Mazzoni, MR; Pasero, G; Pellegrini, P, 1980
)
0.26
" Based on these observations and the fact that authors who have observed an inhibition of the collagen synthesis have used an uncomparibly higher dosage per kilogram of body weight, the authors of this report are so far of the opinion that the dosage they are using (300-600 mg/day) does not significantly influence the speed of wound healing."( [D-penicillamine and wound healing in patients with rheumatoid arthritis].
Bamert, W; Stojan, B; Wiedmer, U,
)
0.13
" An overestimation of rare side-effects of drugs should not block the application of certain medicaments, however, they should be given only in such a high dosage as it is necessary."( [Hematotoxic lesions caused by non-steroidal antirheumatic agents].
Hüge, W; Stobbe, H, 1980
)
0.26
" Moreover, oxyhemoglobin, a scavenger of free NO, suppressed the chemotactic effect of SNAP, whereas LY-83583, a soluble guanylate cyclase inhibitor, inhibited the SNAP-mediated chemotaxis in a dose-response manner."( Exogenous nitric oxide elicits chemotaxis of neutrophils in vitro.
Beauvais, F; Dubertret, L; Michel, L, 1995
)
0.29
"A direct semimicro conductometric method is described for the determination of five pharmaceutically-important thiol compounds, namely: N-acetylcysteine, captopril, D-penicillamine, 6-mercaptopurine and thioguanine, in bulk and in dosage forms."( Conductometric determination of some pharmaceutically important thiol compounds in dosage forms.
Belal, F; Eid, MM; Rizk, MS, 1993
)
0.29
" These findings, together with previously reported data, suggest that treatment should be initiated in a dosage of 1 g/day and that thiopronin-related adverse events are not dose-dependent."( [A comparative controlled trial of 2 administration modalities of tiopronin in rheumatoid arthritis].
Brin, S; Combe, B; Delecoeuillerie, G; Paolozzi, L; Sany, J, 1993
)
0.29
" These two phenomena followed a similar time course and shared a parallel dose-response sensitivity to hrIL-1 beta."( Nitric oxide and energy production in articular chondrocytes.
Evans, CH; Georgescu, HI; Stadler, J; Stefanovic-Racic, M, 1994
)
0.29
" With the aim of learning how the blood thallium altered kinetics and the modifications produced on the tissue accumulation, we administered PCA to white male thallium dosed rabbits."( Penicillamine produces changes in the acute blood elimination and tissue accumulation of thallium.
Careaga-Olivares, J; González-Ramírez, D, 1995
)
0.29
" A dose-response relation was found between 2 and 20 nmol."( [Effect of a nitric oxide donor on optic nerve head circulation].
Azuma, I; Ishida, O; Kojima, S; Oku, H; Shimizu, K; Sugiyama, T, 1996
)
0.29
" Dose-response relationships to both SNAP and AP (0."( Vasodilator action of the S-nitrosothiol, SNAP, in rat isolated perfused lung.
Emery, CJ, 1995
)
0.29
" Dose-response curves for the three drugs on the inhibition of nitrite accumulation in macrophage cultures were obtained."( Evidence that nitric oxide inhibits steroidogenesis in cultured rat granulosa cells.
Dave, S; Farrance, DP; Whitehead, SA, 1997
)
0.3
" Dose-response studies showed that Th1 cells produce optimal levels of IL-2 and a proliferative response, and no detectable NO, when stimulated with relatively low concentrations of antigen or mitogen in vitro."( Inhibition of IL-2 production by nitric oxide: a novel self-regulatory mechanism for Th1 cell proliferation.
Taylor-Robinson, AW, 1997
)
0.3
" There is no evidence that the dosage of drugs metabolized by the CYP3A4 isoenzyme needs to be adjusted for disease activity in RA."( Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis.
Beyeler, C; Bird, HA; Frey, BM, 1997
)
0.3
" A wide variety of unpredictable adverse effects, extremely long half lives and lack of dose-response and concentration-response relationships have added to the confusion."( Transcription factors AP-1 and NF-kappa B: where steroids meet the gold standard of anti-rheumatic drugs.
Handel, ML, 1997
)
0.3
" At 18 weeks the dosage of penicillamine was reduced from 900 mg/d to 750 mg/d."( [Wilson disease and pregnancy. Review of the literature and case report].
Günter, HH; Messner, U; Niesert, S,
)
0.13
" In thoracic aortic rings from CH rats, cumulative dose-response curves to phenylephrine (PE) in the presence of the nitric oxide (NO) synthase inhibitor Nomega-nitro-L-arginine (L-NNA) and the HO inhibitor zinc protoporphyrin 9 (ZnPPIX) elicited increased contractility compared with CH rings treated with only L-NNA."( Role of endothelial carbon monoxide in attenuated vasoreactivity following chronic hypoxia.
Caudill, TK; Kanagy, NL; Resta, TC; Walker, BR, 1998
)
0.3
" Dose-response studies revealed that the inhibitory effects of CNP and ANF on PAI-1 expression were concentration dependent, with IC50s of approximately 1 nmol/L for both natriuretic peptides."( Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system.
Bouchie, JL; Feener, EP; Hansen, H, 1998
)
0.3
" Although the appropriate selection of mouse strains and drug dosage levels has to be considered, these results suggest that the PLNA may be an appropriate screening system for prediction of the allergic or autoimmunity-inducing potentials of low-molecular-weight drugs."( Mouse popliteal lymph node assay for assessment of allergic and autoimmunity-inducing potentials of low-molecular-weight drugs.
Iwaki, Y; Kamimura, Y; Kuninishi, Y; Maki, E; Nakamura, K; Nishida, H; Shinkai, K; Suzuki, R; Takahashi, K; Takahashi, M; Tsutsui, N; Vohr, HW, 1999
)
0.3
" The dose-response for SNAP increases in cyclic GMP was shifted nearly two orders of magnitude lower in the presence of glutathione."( Comparative effects of several nitric oxide donors on intracellular cyclic GMP levels in bovine chromaffin cells: correlation with nitric oxide production.
Ferrero, R; Miras-Portugal, MT; Rodríguez-Pascual, F; Torres, M, 1999
)
0.3
" Total withdrawals were significantly higher in the moderate and high dosage D-penicillamine groups (OR=1."( Penicillamine for rheumatoid arthritis.
Belseck, E; Spooner, C; Suarez-Almazor, ME, 2000
)
0.31
" Total withdrawals were significantly higher in the moderate and high dosage D-penicillamine groups (OR=1."( Penicillamine for treating rheumatoid arthritis.
Belseck, E; Spooner, C; Suarez-Almazor, ME, 2000
)
0.31
" Dose-response curves to IL1beta for gammaGTP activity and nitrite production were observed."( Interleukin-1beta regulates nitric oxide production and gamma-glutamyl transpeptidase activity in sertoli cells.
Cigorraga, SB; Meroni, SB; Suburo, AM,
)
0.13
" The course of skin thickening and the occurrence of renal crisis and of death were examined in a recent randomized controlled 2-year trial of high- dosage DPA (750-1000 mg/d) versus low-dose DPA (125 mg every other day)."( Penicillamine in the treatment of systemic sclerosis.
Clements, PJ, 1999
)
0.3
" Vitamin C inhibited relaxation to GTN but potentiated relaxations to NP and SNAP, causing a parallel shift to a lower concentration range of the log dose-response curve by approximately one log unit at the highest dose."( Divergent effects of vitamin C on relaxations of rabbit aortic rings to acetylcholine and NO-donors.
Chowienczyk, PJ; de Saram, K; Khokher, S; McNeill, KL; Ritter, JM, 2002
)
0.31
" The resulting urinary copper excretion on each dosing schedule was compared."( [Appropriate administration schedule of D-penicillamine for pediatric Wilson's disease patients based on urinary copper excretion].
Fukuoka, N; Hamatani, S; Imai, T; Itoh, S; Kondoh, M; Morita, S; Ohnishi, S; Okada, H, 2002
)
0.31
" The proposed method was successfully applied for the determination of these compounds in their dosage forms."( Spectrophotometric determination of penicillamine and carbocisteine based on formation of metal complexes.
Abdelal, AA; El-Brashy, AM; Metwally, ME; Walash, MI, 2004
)
0.32
" Next, using the quantitative in vivo angiogenesis ELISA, we generated dose-response curves for each compound."( Use of a monoclonal antibody specific for activated endothelial cells to quantitate angiogenesis in vivo in zebrafish after drug treatment.
Eng, K; Lee, J; McGrath, P; Seng, WL, 2004
)
0.32
" We used a high-throughput approach to identify factors that might represent danger signals by profiling hepatic gene expression 6 h after dosing with D-penicillamine (150 mg/kg)."( Gene expression profiling in a model of D-penicillamine-induced autoimmunity in the Brown Norway rat: predictive value of early signs of danger.
Boutros, PC; Li, X; Okey, AB; Séguin, B; Uetrecht, JP, 2005
)
0.33
" Drug dosage was adjusted to maintain free urine cystine level below 100 micromol/mmol creatinine."( Cystinuria in children and young adults: success of monitoring free-cystine urine levels.
Dello Strologo, L; Laurenzi, C; Legato, A; Pastore, A, 2007
)
0.34
"1%, indicating that no interference is observed from concomitants usually present in dosage forms."( A spectrofluorimetric sequential injection method for the determination of penicillamine using fluorescamine in the presence of beta-cyclodextrins.
Al-Kindy, SM; Al-Lawati, ZH; Suliman, FE, 2008
)
0.35
" CSE-induced protein carbonylation exhibited a dose-response relation with CSE concentrations."( Protein carbonylation in THP-1 cells induced by cigarette smoke extract via a copper-catalyzed pathway.
Lin, CC; Su, TH; Wang, TS, 2009
)
0.35
" For Co studies, animals received a single dose of Cuprimine or Syprine, while for Po studies animals were repeatedly dosed at 24-h intervals for a total of 5 doses."( Evaluation of Cuprimine and Syprine for decorporation of (60)Co and (210)Po.
Creim, JA; Curry, TL; Levinson, B; Levitskaia, TG; Luders, T; Morris, JE; Thrall, KD; Woodstock, AD, 2010
)
0.36
" For reasons of safety and efficacy, the pure enantiomer is usually preferred over the racemate in many marketed dosage forms."( Chiral self assembled monolayers as resolving auxiliaries in the crystallization of valine.
Myerson, AS; Singh, A, 2010
)
0.36
" The authors measured spot urinary copper excretion, which gave an indication of the efficacy of treatment and of the sufficient dosage of zinc."( Effects of long-term zinc treatment in Japanese patients with Wilson disease: efficacy, stability, and copper metabolism.
Aoki, T; Fujisawa, T; Fujiwara, J; Harada, M; Horiike, N; Ida, S; Inui, A; Ito, M; Itoh, S; Kodama, H; Kohsaka, T; Ohnishi, S; Sato, M; Shimizu, N; Tamai, H; Yoshino, M, 2010
)
0.36
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" The dosage of 1,500 mg/kg/day proved to be uniformly lethal."( The effects of D-penicillamine on a murine model of oxygen-induced retinopathy.
Ash, JD; Moreau, A; Siatkowski, RM; Yanovitch, TL, 2011
)
0.37
" These cutaneous adverse effects may correlate with the dosage and duration of penicillamine therapy as well as the disease being treated."( Penicillamine revisited: historic overview and review of the clinical uses and cutaneous adverse effects.
Abbas, O; Ishak, R, 2013
)
0.39
" Data about the dosage scheme of zinc sulphate, side effects and efficacy and toxicity of the treatment were collected and recorded in the patient's medical chart at each visit to the hospital."( Gastrointestinal side effects in children with Wilson's disease treated with zinc sulphate.
Avsar, Y; Dądalski, M; Jańczyk, W; Schmidt, H; Socha, P; Wiernicka, A, 2013
)
0.39
" Standardized dosage strategies that address changes in copper pools might improve adherence and reduce side effects."( Clinical considerations for an effective medical therapy in Wilson's disease.
Stremmel, W; Weiss, KH, 2014
)
0.4
" The assay was validated and successfully applied to the assay of drug content and the determination of drug amount released in the dissolution test in the capsule dosage forms."( Smartphone-based Ellman's colourimetric methods for the analysis of d-penicillamine formulation and thiolated polymer.
Chinsriwongkul, A; Ngawhirunpat, T; Opanasopit, P; Patrojanasophon, P; Phadungcharoen, N; Rojanarata, T, 2019
)
0.51
"Appropriate dosing of cystine-binding thiol drugs in the management of cystinuria has been based on clinical stone activity."( Effect of increasing doses of cystine-binding thiol drugs on cystine capacity in patients with cystinuria.
Asplin, JR; Enders, FT; Goldfarb, DS; Malieckal, DA; Mara, K; Modersitzki, F, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
chelatorA ligand with two or more separate binding sites that can bind to a single metallic central atom, forming a chelate.
antirheumatic drugA drug used to treat rheumatoid arthritis.
drug allergenAny drug which causes the onset of an allergic reaction.
copper chelatorA chelator that is any compound containing a ligand (typically organic) which is able to form a bond to a central copper atom at two or more points.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
penicillamineAn alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.
non-proteinogenic alpha-amino acidAny alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
non-proteinogenic alpha-amino acidAny alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
thiolAn organosulfur compound in which a thiol group, -SH, is attached to a carbon atom of any aliphatic or aromatic moiety.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00560.003245.467312,589.2998AID2517
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency12.55940.140911.194039.8107AID2451
phosphopantetheinyl transferaseBacillus subtilisPotency25.11890.141337.9142100.0000AID1490
Microtubule-associated protein tauHomo sapiens (human)Potency16.53110.180013.557439.8107AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency22.38720.011212.4002100.0000AID1030
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency13.44810.000214.376460.0339AID720691
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency5.01190.035520.977089.1251AID504332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency44.66840.354828.065989.1251AID504847
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.01280.005612.367736.1254AID624032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.40002.75008.6000AID1209456
Bile salt export pumpHomo sapiens (human)IC50 (µMol)566.50000.11007.190310.0000AID1209455; AID1473738
Cystathionine gamma-lyaseHomo sapiens (human)IC50 (µMol)270.00000.57002.86098.0000AID1504913
Succinyl-diaminopimelate desuccinylaseHaemophilus influenzae Rd KW20IC50 (µMol)50.00003.30003.30003.3000AID467024
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (36)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cysteine metabolic processCystathionine gamma-lyaseHomo sapiens (human)
lipid metabolic processCystathionine gamma-lyaseHomo sapiens (human)
protein-pyridoxal-5-phosphate linkage via peptidyl-N6-pyridoxal phosphate-L-lysineCystathionine gamma-lyaseHomo sapiens (human)
cysteine biosynthetic process via cystathionineCystathionine gamma-lyaseHomo sapiens (human)
cysteine biosynthetic processCystathionine gamma-lyaseHomo sapiens (human)
transsulfurationCystathionine gamma-lyaseHomo sapiens (human)
endoplasmic reticulum unfolded protein responseCystathionine gamma-lyaseHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionCystathionine gamma-lyaseHomo sapiens (human)
protein sulfhydrationCystathionine gamma-lyaseHomo sapiens (human)
protein homotetramerizationCystathionine gamma-lyaseHomo sapiens (human)
hydrogen sulfide biosynthetic processCystathionine gamma-lyaseHomo sapiens (human)
positive regulation of aortic smooth muscle cell differentiationCystathionine gamma-lyaseHomo sapiens (human)
cellular response to leukemia inhibitory factorCystathionine gamma-lyaseHomo sapiens (human)
negative regulation of apoptotic signaling pathwayCystathionine gamma-lyaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cystathionine gamma-lyase activityCystathionine gamma-lyaseHomo sapiens (human)
protein bindingCystathionine gamma-lyaseHomo sapiens (human)
calmodulin bindingCystathionine gamma-lyaseHomo sapiens (human)
pyridoxal phosphate bindingCystathionine gamma-lyaseHomo sapiens (human)
identical protein bindingCystathionine gamma-lyaseHomo sapiens (human)
L-cystine L-cysteine-lyase (deaminating)Cystathionine gamma-lyaseHomo sapiens (human)
homocysteine desulfhydrase activityCystathionine gamma-lyaseHomo sapiens (human)
L-cysteine desulfhydrase activityCystathionine gamma-lyaseHomo sapiens (human)
selenocystathionine gamma-lyase activityCystathionine gamma-lyaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytosolCystathionine gamma-lyaseHomo sapiens (human)
extracellular exosomeCystathionine gamma-lyaseHomo sapiens (human)
cytoplasmCystathionine gamma-lyaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (152)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID302625Inhibition of bovine ZnCPD pretreated at 0.25 mM assessed as residual enzyme activity in presence of 2.5 uM thionenin after 17 mins2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Catalysis of zinc transfer by D-penicillamine to secondary chelators.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID289327Singlet oxygen scavenging activity by assessed as inhibition of DHR oxidation2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
2-Styrylchromones: novel strong scavengers of reactive oxygen and nitrogen species.
AID265521Distribution of copper in Wistar rat CSF at 5 mg/kg, iv after 1 hr2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.
AID1077167Antibacterial activity against Bacillus thuringiensis after 12 hrs by MTT assay2014European journal of medicinal chemistry, Apr-09, Volume: 76Design and synthesis of 2-styryl of 5-Nitroimidazole derivatives and antimicrobial activities as FabH inhibitors.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID152782Inhibitory concentration against growth of LPS stimulated human peripheral blood mononuclear cells2001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Structure-activity relationships of quinazoline derivatives: dual-acting compounds with inhibitory activities toward both TNF-alpha production and T cell proliferation.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1147028Detoxification of acetaldehyde in aldehyde dehydrogenase inhibitor pyrogallol/ethanol-1-[14C]-treated Sprague-Dawley rat assessed as [14C]-3-acetyl-2,5,5-trimethylthiazolidine-4-carboxylic acid excretion in urine by measuring administered dose of ethanol-1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
2,5,5-Trimethylthiazolidine-4-carboxylic acid, a D(-)-penicillamine-directed pseudometabolite of ethanol. Detoxication mechanism for acetaldehyde.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID409945Inhibition of human recombinant MAOA at 100 uM by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID695851Resistance index, ratio of IC50 for human KB-3-1 cells to IC50 for drug-resistant human KBV1 cells expressing P-gp2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID666942Antioxidant activity assessed as authentic peroxynitrite radical scavenging activity after 5 mins by spectrophotometry2012Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
Evaluation of novel antioxidant triterpenoid saponins from the halophyte Salicornia herbacea.
AID1147027Detoxification of acetaldehyde in aldehyde dehydrogenase inhibitor pargyline/ethanol-1-[14C]-treated Sprague-Dawley rat assessed as [14C]-3-acetyl-2,5,5-trimethylthiazolidine-4-carboxylic acid excretion in urine by measuring administered dose of ethanol-11978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
2,5,5-Trimethylthiazolidine-4-carboxylic acid, a D(-)-penicillamine-directed pseudometabolite of ethanol. Detoxication mechanism for acetaldehyde.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID314066Peroxynitrite scavenging activity assessed as inhibition of DHR 123 oxidation2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
In vitro anti-inflammatory activity of 3-O-methyl-flavones isolated from Siegesbeckia glabrescens.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID302624Inhibition of bovine ZnCPD pretreated at 5 mM assessed as residual enzyme activity in presence of 1 mM ethylenediaminetetraacetic acid within 7 mins2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Catalysis of zinc transfer by D-penicillamine to secondary chelators.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID409951Inhibition of human liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1147029Detoxification of acetaldehyde in aldehyde dehydrogenase inhibitor disuifiram/ethanol-treated rat assessed as reduction of blood acetaldehyde level at 8 mmol/kg, po administered 24 hrs prior to ethanol treatment measured after 1 hr by head space gas chrom1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
2,5,5-Trimethylthiazolidine-4-carboxylic acid, a D(-)-penicillamine-directed pseudometabolite of ethanol. Detoxication mechanism for acetaldehyde.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1147026Detoxification of acetaldehyde in aldehyde dehydrogenase inhibitor disuifiram/ethanol-1-[14C]-treated Sprague-Dawley rat assessed as [14C]-3-acetyl-2,5,5-trimethylthiazolidine-4-carboxylic acid excretion in urine by measuring administered dose of ethanol-1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
2,5,5-Trimethylthiazolidine-4-carboxylic acid, a D(-)-penicillamine-directed pseudometabolite of ethanol. Detoxication mechanism for acetaldehyde.
AID1147022Detoxification of acetaldehyde in ethanol-1-[14C]-treated Sprague-Dawley rat assessed as [14C]-3-acetyl-2,5,5-trimethylthiazolidine-4-carboxylic acid excretion in urine by measuring administered dose of ethanol-1-[14C] at 8.1 mmol/kg, po administered with1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
2,5,5-Trimethylthiazolidine-4-carboxylic acid, a D(-)-penicillamine-directed pseudometabolite of ethanol. Detoxication mechanism for acetaldehyde.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID182194Antiinflammatory activity against collagen II arthritis in rats, activity% inhibition in injected paw edema1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID187884compound was tested for antiinflammatory activity against collagen II arthritis in rats,1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID175768Delayed Type hypersensitivity (DTH) is measured by increase in ear thickness 24 hours after antigen injection into pinna1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID666943Antioxidant activity assessed as morpholinosydnonimine-derived peroxynitrite free radical scavenging activity after 5 mins by spectrophotometry2012Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
Evaluation of novel antioxidant triterpenoid saponins from the halophyte Salicornia herbacea.
AID467024Inhibition of Haemophilus influenzae recombinant DapE2009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Inhibitors of bacterial N-succinyl-L,L-diaminopimelic acid desuccinylase (DapE) and demonstration of in vitro antimicrobial activity.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID377832Antioxidant activity assessed as 3-morpholinosydnonimine-derived peroxynitrite free radical scavenging activity after 30 mins2005Journal of natural products, Apr, Volume: 68, Issue:4
Chemical constituents of the fruits of Morinda citrifolia (Noni) and their antioxidant activity.
AID265520Distribution of copper per 100 ml of Wistar rat blood at 5 mg/kg, iv after 1 hr2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID377831Antioxidant activity assessed as authentic peroxynitrite free radical scavenging activity after 30 mins2005Journal of natural products, Apr, Volume: 68, Issue:4
Chemical constituents of the fruits of Morinda citrifolia (Noni) and their antioxidant activity.
AID209812Inhibitory concentration against T cell proliferation determined by MTS assay using concanavalin A (Con A)-stimulated mice spleen cells; NT = Not tested2001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Structure-activity relationships of quinazoline derivatives: dual-acting compounds with inhibitory activities toward both TNF-alpha production and T cell proliferation.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1077164Antibacterial activity against Escherichia coli after 12 hrs by MTT assay2014European journal of medicinal chemistry, Apr-09, Volume: 76Design and synthesis of 2-styryl of 5-Nitroimidazole derivatives and antimicrobial activities as FabH inhibitors.
AID1504913Inhibition of cystathionine gamma-lyase (unknown origin)2017ACS medicinal chemistry letters, Dec-14, Volume: 8, Issue:12
2-Arylidene Hydrazinecarbodithioates as Potent, Selective Inhibitors of Cystathionine γ-Lyase (CSE).
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID302623Inhibition of bovine ZnCPD pretreated at 0.25 mM assessed as residual enzyme activity in presence of 1 mM ethylenediaminetetraacetic acid within 20 mins2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Catalysis of zinc transfer by D-penicillamine to secondary chelators.
AID152781Inhibitory concentration against TNF-alpha production from human peripheral blood mononuclear cells stimulated by LPS2001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Structure-activity relationships of quinazoline derivatives: dual-acting compounds with inhibitory activities toward both TNF-alpha production and T cell proliferation.
AID182193Antiinflammatory activity against collagen II arthritis in rats, activity % inhibition in noninjected paw edema1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.
AID187883Compound was tested for antiinflammatory activity against collagen II arthritis in rats,1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.
AID1077165Antibacterial activity against Pseudomonas aeruginosa after 12 hrs by MTT assay2014European journal of medicinal chemistry, Apr-09, Volume: 76Design and synthesis of 2-styryl of 5-Nitroimidazole derivatives and antimicrobial activities as FabH inhibitors.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID265522Distribution of copper in Wistar rat brain cortex at 5 mg/kg, iv after 1 hr2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID172966Compound was tested for antiinflammatory activity by immune response to collagen II antigen in rats, antibody titer was determined by passive hemagglutinination1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.
AID302622Inhibition of bovine ZnCPD pretreated for 200 seconds at 1.5 mM assessed as transfer of zinc(II) from ZnCPD to chelator 4-(2-pyridylazo)-resorcinol2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Catalysis of zinc transfer by D-penicillamine to secondary chelators.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID26336pKa value was determined2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
Equilibrium and kinetics studies of transnitrosation between S-nitrosothiols and thiols.
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1075914Antioxidant activity assessed as peroxynitrite scavenging activity at 1 to 10 uM by DHR 123 assay2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
MHY884, a newly synthesized tyrosinase inhibitor, suppresses UVB-induced activation of NF-κB signaling pathway through the downregulation of oxidative stress.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1147024Detoxification of acetaldehyde in ethanol-1-[14C]-treated Sprague-Dawley rat assessed as [14C]-3-acetyl-2,5,5-trimethylthiazolidine-4-carboxylic acid excretion in urine by measuring administered dose of ethanol-1-[14C] at 8.1 mmol/kg, ip administered 1 hr1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
2,5,5-Trimethylthiazolidine-4-carboxylic acid, a D(-)-penicillamine-directed pseudometabolite of ethanol. Detoxication mechanism for acetaldehyde.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID695876Cytotoxicity against drug-resistant human KBV1 cells expressing P-gp incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID409949Inhibition of human liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1147023Detoxification of acetaldehyde in ethanol-1-[14C]-treated Sprague-Dawley rat assessed as [14C]-3-acetyl-2,5,5-trimethylthiazolidine-4-carboxylic acid excretion in urine by measuring administered dose of ethanol-1-[14C] at 8.1 mmol/kg, po administered 1 hr1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
2,5,5-Trimethylthiazolidine-4-carboxylic acid, a D(-)-penicillamine-directed pseudometabolite of ethanol. Detoxication mechanism for acetaldehyde.
AID265523Distribution of copper in Wistar rat brain corpus callosum at 5 mg/kg, iv after 1 hr2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1077166Antibacterial activity against Bacillus subtilis after 12 hrs by MTT assay2014European journal of medicinal chemistry, Apr-09, Volume: 76Design and synthesis of 2-styryl of 5-Nitroimidazole derivatives and antimicrobial activities as FabH inhibitors.
AID695877Cytotoxicity against human KB-3-1 cells incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1147025Detoxification of acetaldehyde in aldehyde dehydrogenase inhibitor disuifiram/ethanol-1-[14C]-treated Sprague-Dawley rat assessed as [14C]-3-acetyl-2,5,5-trimethylthiazolidine-4-carboxylic acid excretion in urine by measuring administered dose of ethanol-1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
2,5,5-Trimethylthiazolidine-4-carboxylic acid, a D(-)-penicillamine-directed pseudometabolite of ethanol. Detoxication mechanism for acetaldehyde.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID579347Detoxification activity against lead-induced toxicity in mouse assessed as reduction lead level in liver per gram of organ at 0.4 mmol/kg, ip qd for 5 days measured 24 hrs last post dose by synchrotron X-ray fluorescence analysis2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Lead detoxification activities and ADMET hepatotoxicities of a class of novel 5-(1-carbonyl-L-amino-acid)-2,2-dimethyl-[1,3]dithiolane-4-carboxylic acids.
AID378809Antioxidant activity assessed as peroxynitrite scavenging activity by fluorescence spectroscopy2006Journal of natural products, Oct, Volume: 69, Issue:10
Antioxidative phenolics from the fresh leaves of Ternstroemia japonica.
AID579348Detoxification activity against lead-induced toxicity in mouse assessed as reduction lead level in feces at 0.4 mmol/kg, ip qd for 5 days measured 24 hrs last post dose by synchrotron X-ray fluorescence analysis2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Lead detoxification activities and ADMET hepatotoxicities of a class of novel 5-(1-carbonyl-L-amino-acid)-2,2-dimethyl-[1,3]dithiolane-4-carboxylic acids.
AID1378838Peroxynitrite scavenging activity assessed as inhibition of DHR 123 oxidation after 5 mins in presence of SIN-1 by fluorescence assay2017Journal of natural products, 08-25, Volume: 80, Issue:8
Peroxynitrite-Scavenging Glycosides from the Stem Bark of Catalpa ovata.
AID579345Detoxification activity against lead-induced toxicity in mouse assessed as reduction lead level in brain per gram of organ at 0.4 mmol/kg, ip qd for 5 days measured 24 hrs last post dose by synchrotron X-ray fluorescence analysis2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Lead detoxification activities and ADMET hepatotoxicities of a class of novel 5-(1-carbonyl-L-amino-acid)-2,2-dimethyl-[1,3]dithiolane-4-carboxylic acids.
AID579360Efflux ratio of permeability from apical to basolateral side over basolateral to apical side in human Caco2 cells at 4 mM up to 120 mins by HPLC analysis2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Lead detoxification activities and ADMET hepatotoxicities of a class of novel 5-(1-carbonyl-L-amino-acid)-2,2-dimethyl-[1,3]dithiolane-4-carboxylic acids.
AID450165Cytoprotective activity against MG-induced cytotoxicity in human EAhy926 cells assessed as viable cells at 1 mM after overnight incubation by MTT assay2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
N-Terminal 2,3-diaminopropionic acid (Dap) peptides as efficient methylglyoxal scavengers to inhibit advanced glycation endproduct (AGE) formation.
AID450158Inhibition of alpha-dicarbonyls-induced advanced glycation end product formation assessed as protection against 50 eq. MG-induced insulin degradation at 3.75 mM after 24 hrs by RP-HPLC2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
N-Terminal 2,3-diaminopropionic acid (Dap) peptides as efficient methylglyoxal scavengers to inhibit advanced glycation endproduct (AGE) formation.
AID256510Inhibitory activity against TACE[ADAM metallopeptidase domain 17] in isolated enzyme assay2005Bioorganic & medicinal chemistry letters, Oct-01, Volume: 15, Issue:19
Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.
AID450166Cytotoxicity in human EAhy926 cells assessed as viable cells at 1 mM after overnight incubation by MTT assay2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
N-Terminal 2,3-diaminopropionic acid (Dap) peptides as efficient methylglyoxal scavengers to inhibit advanced glycation endproduct (AGE) formation.
AID579359Apparent permeability from basolateral to apical side of human Caco2 cells at 4 mM up to 120 mins by HPLC analysis2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Lead detoxification activities and ADMET hepatotoxicities of a class of novel 5-(1-carbonyl-L-amino-acid)-2,2-dimethyl-[1,3]dithiolane-4-carboxylic acids.
AID579344Detoxification activity against lead-induced toxicity in mouse assessed as reduction lead level in femurs per gram of organ at 0.4 mmol/kg, ip qd for 5 days measured 24 hrs last post dose by synchrotron X-ray fluorescence analysis2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Lead detoxification activities and ADMET hepatotoxicities of a class of novel 5-(1-carbonyl-L-amino-acid)-2,2-dimethyl-[1,3]dithiolane-4-carboxylic acids.
AID579358Apparent permeability from apical to basolateral side of human Caco2 cells at 4 mM up to 120 mins by HPLC analysis2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Lead detoxification activities and ADMET hepatotoxicities of a class of novel 5-(1-carbonyl-L-amino-acid)-2,2-dimethyl-[1,3]dithiolane-4-carboxylic acids.
AID579349Detoxification activity against lead-induced toxicity in mouse assessed as reduction lead level in urine at 0.4 mmol/kg, ip qd for 5 days measured 24 hrs last post dose by synchrotron X-ray fluorescence analysis2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Lead detoxification activities and ADMET hepatotoxicities of a class of novel 5-(1-carbonyl-L-amino-acid)-2,2-dimethyl-[1,3]dithiolane-4-carboxylic acids.
AID579346Detoxification activity against lead-induced toxicity in mouse assessed as reduction lead level in kidney per gram of organ at 0.4 mmol/kg, ip qd for 5 days measured 24 hrs last post dose by synchrotron X-ray fluorescence analysis2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Lead detoxification activities and ADMET hepatotoxicities of a class of novel 5-(1-carbonyl-L-amino-acid)-2,2-dimethyl-[1,3]dithiolane-4-carboxylic acids.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6,905)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903835 (55.54)18.7374
1990's1547 (22.40)18.2507
2000's1034 (14.97)29.6817
2010's373 (5.40)24.3611
2020's116 (1.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 84.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index84.30 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index142.40 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (84.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials312 (4.21%)5.53%
Trials0 (0.00%)5.53%
Reviews620 (8.36%)6.00%
Reviews0 (0.00%)6.00%
Case Studies1,093 (14.74%)4.05%
Case Studies0 (0.00%)4.05%
Observational5 (0.07%)0.25%
Observational0 (0.00%)0.25%
Other5,385 (72.62%)84.16%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Post Marketing Surveillance Study of Cuprimine (MK-0172-001) [NCT01374282]0 participants Expanded AccessNo longer available
Balloon Angioplasty of Dialysis AV Fistulae: Effect of Local Delivery of Inhibitors of Lysyl Oxidase (LysoLox) on Serial Angioplasty and Time to Restenosis [NCT03106948]Phase 230 participants (Anticipated)Interventional2017-02-01Recruiting
The Individual Therapy for Patients With Wilson's Disease [NCT03957720]Early Phase 1400 participants (Anticipated)Interventional2019-03-15Recruiting
A Phase 2/3 Trial of d-Penicillamine Chelation in Lead-Poisoned Children [NCT00552630]Phase 2/Phase 30 participants (Actual)Interventional2007-09-30Withdrawn
CHELATE STUDY: Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease [NCT03539952]Phase 377 participants (Actual)Interventional2018-09-03Completed
Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria [NCT02125721]Phase 410 participants (Actual)Interventional2012-06-30Completed
Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer: a Single-center, Single-arm, Phase II Clinical Trial [NCT06103617]Phase 210 participants (Anticipated)Interventional2023-11-15Recruiting
Phase II Study of Penicillamine and Reduction of Copper for Angiosuppressive Therapy of Adults With Newly Diagnosed Glioblastoma [NCT00003751]Phase 240 participants (Anticipated)Interventional1999-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02125721 (1) [back to overview]Cystine Capacity
NCT03539952 (3) [back to overview]24-hour Urinary Copper Excretion (UCE)
NCT03539952 (3) [back to overview]Clinical Global Impression of Change (CGIC) Rating Scale
NCT03539952 (3) [back to overview]Serum NCC Concentration

Cystine Capacity

We will test for a negative correlation between progressive increases in doses of thiol drugs and cystine capacity (NCT02125721)
Timeframe: 4 weeks on assigned therapy

Interventionmg/L (Mean)
Increasing Doses of CBTD43.1

[back to top]

24-hour Urinary Copper Excretion (UCE)

24-hour urinary copper excretion (μg/ 24 hr) from urine collected by the patient over a 24-hour period. (NCT03539952)
Timeframe: Week 36

Interventionμg/24 hours (Mean)
TETA 4HCL274.5
Penicillamine510.8

[back to top]

Clinical Global Impression of Change (CGIC) Rating Scale

"The clinician will rate the change in the patient's Wilson's disease relative to the prior study clinic visit using a 7-point scale to a specific statement: 'Please rate the change in the overall severity of the patients Wilson's disease compared to the previous study clinic visit.~Available options were (1) very much improved; (2) much improved; (3) minimally improved; (4) no change; (5) minimally worse; (6), much worse; or (7) very much worse." (NCT03539952)
Timeframe: Week 36

Interventionscore on a scale (Mean)
Penicillamine4.1
TETA 4HCL3.9

[back to top]

Serum NCC Concentration

The primary outcome of efficacy was serum NCC by speciation assay (μg/L), with comparative analysis of mean difference between the two groups 24 weeks after randomization. The non-inferiority margin was set at -50 μg/L. (NCT03539952)
Timeframe: Week 36

Interventionµg/L (Mean)
Penicillamine Arm46.5
TETA 4HCL Arm58.7

[back to top]